STAA

Business Context and Reporting Period

Company: STAAR Surgical Company
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 30, 2007
Business Overview: STAAR develops and manufactures visual implants and ophthalmic products, primarily intraocular lenses (IOLs) for cataract surgery and the Visian ICL for refractive correction. The company operates globally with manufacturing sites in the U.S. and Switzerland.

Key Financial Metrics

Note: Total Debt includes $1,812k current notes, $609k current capital leases, $1,158k long-term capital leases, and $3,733k long-term note payable.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 10.8% year-over-year, driven primarily by a 52% increase in Visian ICL sales ($3.6M vs $2.4M). International sales grew 20% to $9.8M, while U.S. sales declined 3% to $5.1M.
• Expense Increases: Marketing and selling expenses rose 19.1% to $6.1M. This increase was largely due to approximately $800,000 in investigation costs related to fraud at the German subsidiary (Domilens) and increased U.S. headcount.
• Debt Financing: On March 21, 2007, the company secured a $4.0 million unsecured promissory note from Broadwood Partners, L.P. at 10% interest, accompanied by warrants to purchase 70,000 shares.
• Working Capital: Accounts receivable increased by $0.6M, and Days Sales Outstanding (DSO) rose from 39 to 43 days.

Outlook, Risks, and Unusual Items

Management Commentary and Strategy

• Profitability Path: Management identifies significant U.S. sales of the Visian ICL as the primary near-term path to profitability. Long-term strategy involves reversing the decline in U.S. cataract market share through new product introductions (Collamer IOLs).
• Capital Raise: Subsequent to the quarter end (May 1, 2007), the company completed a public offering of 3.6 million shares at $5.00/share, yielding approximately $16.6 million in net proceeds. Proceeds are intended to repay the Broadwood note and fund working capital.
• Regulatory Status: The company is preparing an amendment to the FDA Pre-Market Approval (PMA) application for the Toric ICL (TICL) following comments from the FDA Office of Device Evaluation.

Risks and Contingencies

• Internal Control Weakness: The company identified a material weakness in internal controls over financial reporting due to fraud at its German subsidiary, Domilens GmbH. The former president admitted to diverting approximately $400,000 in assets and generating $1.0 million in unreported proceeds between 2001 and 2006. The company has reserved $700,000 for potential additional taxes.
• FDA Compliance: The FDA's Bioresearch Monitoring Program (BIMO) issued eight Inspectional Observations (Form 483) regarding clinical trial records for the TICL application. While the company does not believe this affects study integrity, FDA approval is not guaranteed.
• Liquidity: The company has a history of losses and negative operating cash flows. While the recent equity offering improves liquidity, the company may require additional financing if profitability is not achieved.

Investor Verification Checklist

• Equity Offering Impact: Verify the final net proceeds and allocation of the $16.6M raised in May 2007, specifically the repayment of the Broadwood note.
• FDA TICL Approval: Monitor the status of the amended PMA application for the Toric ICL and any further FDA observations.
• German Subsidiary Remediation: Confirm the effectiveness of new internal controls at Domilens GmbH and the resolution of tax liabilities with the German Ministry of Finance.
• U.S. Cataract Sales Trend: Track quarterly U.S. cataract sales to determine if the decline is reversing with new product introductions.
• Debt Covenants: Review compliance with financial covenants on the Wells Fargo credit facility, which currently has no availability due to covenant restrictions.